Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 19 citing articles:

Current State and Future Directions in the Therapy of ALS
Laura Tzeplaeff, Sibylle Wilfling, Maria Viktoria Requardt, et al.
Cells (2023) Vol. 12, Iss. 11, pp. 1523-1523
Open Access | Times Cited: 59
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents
Stephen A. Johnson, Ton Fang, Fabiola De Marchi, et al.
Drugs (2022) Vol. 82, Iss. 13, pp. 1367-1388
Closed Access | Times Cited: 64
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JingSi Jiang, Yan Wang, Min Deng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 50
Opinion: more mouse models and more translation needed for ALS
Elizabeth Fisher, Linda Greensmith, Andrea Malaspina, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 24
The novel T107I Inherited prion disease can present as a clinical and biomarker mimic of familial Alzheimer’s disease
Leah Holm-Mercer, Thomas Coysh, Tze How Mok, et al.
Journal of Neurogenetics (2025), pp. 1-7
Open Access | Times Cited: 1
Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators
Daphne N. Weemering, Anita Beelen, Tessa Kliest, et al.
Neurology (2024) Vol. 103, Iss. 1
Open Access | Times Cited: 7
Unraveling the Multifaceted Insights into Amyotrophic Lateral Sclerosis: Genetic Underpinnings, Pathogenesis, and Therapeutic Horizons
Ramaish Sharma, Zuber Khan, Sidharth Mehan, et al.
Mutation Research/Reviews in Mutation Research (2024) Vol. 794, pp. 108518-108518
Closed Access | Times Cited: 5
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus
Charis Wong, Jenna M. Gregory, Jing Liao, et al.
BMJ Open (2023) Vol. 13, Iss. 2, pp. e064169-e064169
Open Access | Times Cited: 10
Innovative trial designs in amyotrophic lateral sclerosis: balancing efficiency and precision
Dongsheng Fan
The Lancet Neurology (2025) Vol. 24, Iss. 6, pp. 473-474
Closed Access
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial
Suvankar Pal, Jeremy Chataway, Robert Swingler, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 11, pp. 1097-1107
Open Access | Times Cited: 3
The importance of clinical importance when determining the target difference in sample size calculations
Richard A. Parker, Jonathan Cook
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 8
Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis
Loreto Martínez-González, Ana Martı́nez
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 2, pp. 141-160
Open Access | Times Cited: 7
A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia
Sarmi Sri, Adam Greenstein, Alessandra Granata, et al.
Cerebral Circulation - Cognition and Behavior (2023) Vol. 5, pp. 100189-100189
Open Access | Times Cited: 7
Current neuroprotective therapies and future prospects for motor neuron disease
Laura J. Evans, David O’Brien, Pamela J. Shaw
International review of neurobiology (2024), pp. 327-384
Closed Access | Times Cited: 2
From use of omics to systems biology: Identifying therapeutic targets for amyotrophic lateral sclerosis
Lydia M. Castelli, Rosario Vasta, Scott P. Allen, et al.
International review of neurobiology (2024), pp. 209-268
Closed Access | Times Cited: 1
Living systematic review and comprehensive network meta-analysis of ALS clinical trials: study protocol
Floris T van Loon, Georgios Seitidis, Dimitris Mavridis, et al.
BMJ Open (2024) Vol. 14, Iss. 10, pp. e087970-e087970
Open Access | Times Cited: 1
Statistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART)
Richard A. Parker, Christopher J. Weir, Tra My Pham, et al.
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 3
A new era of drug discovery for amyotrophic lateral sclerosis
Jinsy Andrews
The Lancet Neurology (2024) Vol. 23, Iss. 11, pp. 1070-1072
Closed Access
Theme 09 - Clinical Trials and Trial Design

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2023) Vol. 24, Iss. sup1, pp. 209-229
Open Access
Mitochondria and Energy Metabolism in the Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis
Csaba Konràd, Giovanni Manfredi
Oxford University Press eBooks (2023)
Closed Access
Page 1

Scroll to top